According to filings with the U.S. Securities and Exchange Commission, Joana Goncalves, Chief Medical Officer (CMO) of Oruka Therapeutics, Inc. (NASDAQ: ORKA), sold a total of 7,000 shares of the company's common stock valued at $432,935 on May 15, 2026. The sale prices for these shares ranged between $60.93 and $63.52 per share. Notably, these transactions were executed in adherence to a Rule 10b5-1 trading plan that had been initially established on September 19, 2025.
This insider selling activity takes place as Oruka Therapeutics' stock has recently shown substantial appreciation. Data from InvestingPro indicates the company's stock has surged by over 515% over the past year. Currently, the biotech firm maintains a market capitalization of $3.72 billion. However, analysis provided by InvestingPro suggests that, despite the strong performance, the stock may be considered overvalued at its current price levels.
Prior to the reported sales, Goncalves had engaged in acquisitions of the company's common stock on the same date. Specifically, she acquired 7,000 shares. These purchases were made through two mechanisms: the exercise of employee stock options and the use of employee warrants. The total value of these initial acquisitions amounted to $51,240.
Details of Stock Transactions
The executed sales transactions involving 7,000 shares included specific batches at varying weighted average prices and individual ranges:
- First Batch: 4,800 shares were sold with a weighted average price of $61.5614 per share. The individual transaction prices for this group spanned from $60.93 to $61.90.
- Second Batch: Another 2,100 shares were disposed of at a weighted average price of $62.423 per share. The specific individual transaction prices here ranged from $62.02 to $62.89.
- Third Batch: Finally, 100 shares were sold at a fixed price of $63.52 per share.
Conversely, the acquisitions component involved:
- Options Exercise: 3,500 shares were obtained through the exercise of employee stock options, which carried an exercise price of $6.84 per share.
- Warrants Exercise: An additional 3,500 shares were acquired from the exercise of employee warrants, with these carrying an exercise price of $7.80 per share.
Current Holdings and Corporate Developments
Following all recorded transactions, Joana Goncalves' direct holdings in Oruka Therapeutics common stock total 33,377 shares. Beyond the insider activity, Oruka Therapeutics has recently announced positive interim results stemming from its EVERLAST-A Phase 2a trial for ORKA-001, a monoclonal antibody designed for moderate-to-severe plaque psoriasis.
These clinical updates have generated notable interest among market analysts and led to several target price adjustments. For instance, H.C. Wainwright raised its price target for Oruka Therapeutics to $120. Clear Street adjusted its target to $131, maintaining a Buy rating on the stock. Furthermore, Barclays increased its price target significantly, setting it at $160. This higher valuation from Barclays was predicated on potential peak sales estimates of $7 billion for ORKA-001 and an additional $2.6 billion for ORKA-002.
Recent Capital Raises
The company has also been active in raising capital through equity offerings. Oruka Therapeutics priced a substantial $700 million stock offering at $72.50 per share, anticipating that these funds would cover gross proceeds before factoring in expenses. Additionally, the firm launched another $500 million stock offering, which included granting underwriters an option to purchase supplementary shares over a 30-day period.
These multifaceted developments - encompassing positive clinical trial data, elevated analyst projections, and significant capital raises - collectively underscore the company's continued progress and the favorable reception of its pipeline by industry experts. The analysis confirms that Goncalves' sales were executed using pre-established trading plans, while her purchases utilized the exercise of employee options and warrants.